Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Trial of Trehalose for the Treatment of Oculopharyngeal Muscular Dystrophy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Trehalose (Primary)
- Indications Oculopharyngeal muscular dystrophy
- Focus Therapeutic Use
- Sponsors Bioblast Pharma; Seelos Therapeutics
- 10 Jan 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Feb 2019 According to a Bioblast Pharma media release, under the terms of the agreement, Seelos will pay Bioblast a payment of dollar 3.5 million in two instalments, dollar 1.5 million payable upon closing of the sale and the other dollar 2.0 million will be paid upon the first anniversary of the closing of the sale. Potential additional milestone payments of up to dollar 17.0 million will be made upon completion of this clinical study and approval of a NDA by the FDA, as well as royalties.
- 19 Feb 2019 According to a Bioblast Pharma media release, Trehalose clinical development programs including this phase II trial has been sold out to Seelos Therapeutics, Inc.